GI ReFacto To Launch In 3rd Quarter; Bayer Predicts Kogenate FS In 2nd Half
This article was originally published in Pharmaceutical Approvals Monthly
Genetics Institute’s planned third-quarter launch of ReFacto means that two albumin-free recombinant factor VIII products could enter the market in close proximity.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class